Press

Irwin Naturals Inc Announces Normal Course Issuer Bid for Subordinate Voting Shares of the Corporation

Sep 24 • 3 min read

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X) announced today its intention to commence a normal course issuer bid, under which the Company may purchase up to 75,466 of the Company’s Subordinate Voting Shares over a 12-month period, representing approximately 5% of its issued and outstanding SVS as of September 26, 2022. The Company is…

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Sep 24 • 5 min read

Optimi Health Corp. (CSE: OPTI | OTCQX: OPTHF | FRA: 8BN), a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and other psychedelic substances, most notably MDMA, is pleased to announce that in conjunction with ATMA Journey Centers, the companies have confirmed their intent to proceed with a Phase…

Core One Labs Signs Letter of Intent with GMP Manufacturing Partner for Production of Proprietary Psychedelic Compounds

Sep 24 • 4 min read

Core One Labs Inc. (CSE:COOL), (OTCQB:CLABF), (Frankfurt:LD6, WKN:A3CSSU) is pleased to announce it has entered into a Letter of Intent with Medelys Laboratories International Inc. dated effective September 21, 2022, for the purpose of manufacturing the Company’s proprietary psychedelic active pharmaceutical ingredient (API) products for Core One and its subsidiaries. Under the Manufacturing Arrangement, it is…

Mydecine Innovations Group Announces Closing Under Share Subscription Agreement and Welcomes New CFO

Sep 24 • 3 min read

Mydecine Innovations Group Inc. (NEO: MYCO | OTC: MYCOF | FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common Share Subscription Agreement with a third-party…

Delix Therapeutics Expands World-Class Team with First Head of R&D

Sep 23 • 3 min read

Delix Therapeutics, a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions, today announced the appointment of Dr. Eliseo Salinas as Head of Research & Development. Dr. Salinas will support the continued acceleration and expansion of Delix’s world-class discovery, preclinical, and clinical pipeline of non-hallucinogenic, neuroplasticity-promoting psychoplastogens. “With a library containing thousands of psychedelic-inspired, non-hallucinogenic…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455